Steven Badin, MD
Critical Care Medicine · Brooklyn, NYNPI 1932147873
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boehringer Ingelheim accounts for 60.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $1,406 and has fallen 84.7% since, to $215 in 2025. Among critical care medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $46.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- GSK$480
- AstraZeneca$236
- Sanofi$203
- Baxter Healthcare$149
- Hologic Sales And Service, LLC$125
- plus $857 from 17 others
What the payments were for
- Consulting fees$1493%
- Food & beverage$5,02697%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 45 | $3,142 |
| GSK | 20 | $480 |
| AstraZeneca | 6 | $236 |
| Sanofi | 6 | $203 |
| Baxter Healthcare | 2 | $149 |
| Hologic Sales And Service, LLC | 1 | $125 |
| Amgen | 1 | $125 |
| Philips North America LLC | 2 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $96 |
| Genentech USA, Inc. | 5 | $94 |
| Jazz Pharmaceuticals Inc. | 3 | $61 |
| Electromed, Inc. | 3 | $58 |
| Novartis | 2 | $48 |
| Merck | 2 | $36 |
| Neurelis, Inc. | 1 | $35 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,191 in reported general payments places this provider in the 90th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProcritEpoetin Alfa | 84 | $81,704 |
| EliquisApixaban | 171 | $53,363 |
| SantylCollagenase Clostridium Hist. | 38 | $51,828 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $40,993 |
| RetacritEpoetin Alfa-Epbx | 46 | $19,783 |
| MounjaroTirzepatide | 13 | $13,877 |
| JanuviaSitagliptin Phosphate | 26 | $10,467 |
| OzempicSemaglutide | 11 | $9,970 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 26 | $9,591 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,099 |
| XareltoRivaroxaban | 28 | $7,683 |
| AranespDarbepoetin Alfa In Polysorbat | 14 | $7,396 |
| Budesonide | 40 | $5,965 |
| EntrestoSacubitril/Valsartan | 12 | $4,535 |
| TradjentaLinagliptin | 17 | $4,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $480 | $49,09269 claims |
| MerckJanuvia | $36 | $10,46726 claims |
| AmgenAranesp | $125 | $7,39614 claims |
| NovartisEntresto | $48 | $4,53512 claims |
| Boehringer IngelheimTradjenta | $3,142 | $4,48917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 critical care medicine providers in New York.
Other critical care medicine in Brooklyn
- Joshua RosenbergBrooklyn$881K
- Mohammad ZamanBrooklyn$13K
- Yizhak KupferBrooklyn$8K
- Chetana PendkarBrooklyn$7K
- Daniel BuchneaBrooklyn$4K
- Samir FahmyBrooklyn$4K
- Alibel BelloBrooklyn$4K
- Peter DicpinigaitisBronx$241K
- Roxana SulicaNew York$211K
- Boris ShkolnikAlbany$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.